OXALIPLATIN INDUCED PULMONARY FIBROSIS: A CASE REPORT

Oxaliplatin is part of the standard chemotherapy regimens for treating colorectal carcinoma. Pulmonary fibrosis is a serious but rare side effect of oxaliplatin treatment, which resulted in patient death in more than half of the reported cases. The precise pathophysiological mechanism of this phenom...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavlović, Mirjana, Šeparović, Robert, Silovski, Tajana, Tečić Vuger, Ana, Jurić, Andreja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253075/
https://www.ncbi.nlm.nih.gov/pubmed/34285449
http://dx.doi.org/10.20471/acc.2020.59.04.25
Descripción
Sumario:Oxaliplatin is part of the standard chemotherapy regimens for treating colorectal carcinoma. Pulmonary fibrosis is a serious but rare side effect of oxaliplatin treatment, which resulted in patient death in more than half of the reported cases. The precise pathophysiological mechanism of this phenomenon has not been clarified yet. Analysis of the reported cases strongly suggests that early diagnosis and immediate corticosteroid treatment are crucial for better prognosis. Here we report a case of pulmonary fibrosis related to the FOLFOX regimen in a patient with early colorectal carcinoma.

Ejemplares similares